Programme Overview

Friday 02 October 2026
18:00 – 19:00 Registration Opens
19:00 – 19:05 Welcome: Prof Vernon Louw
19:05 – 20:15 SYMPOSIUM: CLL
Sponsored by AstraZeneca
Chair: Prof Vernon Louw
Topic: Bridging evidence and practice: BTKi inhibition in CLL
Speaker: Dr Romana Jassat
Panellists: Dr Gamuchirai Tadzimirwa and Dr Michael Cass
Q&A
20:15 – 22:00 Canapés and Conversations
Saturday 03 October 2026
07:00 Registration & Exhibition Opens
08:00 – 08:05 Conference Opening: Prof Vernon Louw
08:10 – 09:10 SYMPOSIUM: CLL
Sponsored by BeOne
Chair: Dr Perry Loebenberg
Evolving strategies in CLL: Optimizing care for long-term outcomes
Speaker: Dr Talha Munirr
Q&A
09:10 – 09:25 Standing on the Shoulders of Giants
09:25 – 09:30 “10/100” programme: Meet our Bursars
09:30 – 10:30 Session 1: Multiple Myeloma
Chair: Dr Lucille Singh
09:30 – 10:05 Topic: Transplant -Ineligible multiple myeloma
Speaker:  Prof M Mohty
Sponsored by J&J
10:05 – 10:15 Case Study
Speaker: Dr Richard Siebert
10:15 – 10:30 Q&A
10:30 – 10:50 Refreshment Break
10:50 – 12:00 Session 2: Image Matters Nurses Session
Click to view
Chair: Dr Estelle Verburgh
10:50 – 11:20 Topic: The evolving role of Nuclear Medicine in haematological malignancies
Speaker: Dr Bawinile Hadebe
11:20 – 11:50 Topic: The intersection of Interventional Radiology and the bleeding patient
Speaker: Dr Gary Sudwartz
11:50 – 12:00 Panel Discussion and Q&A
12:00 – 12:10 Campaigning for Cancer – a call to Action
12:10 – 13:00 Lunch
13:00 – 14:05 Session 3: Mantle Cell Lymphoma
Chair: Prof M Mohty
13:00 – 13:20 Topic: Pathology updates in MCL
Speaker: Dr Tomek Piorkowski
Sponsored by PathCare
13:20 – 13:50 Topic: Advances in the management of MCL
Speaker: Prof Talha Munir
Sponsored by BeOne
13:50 – 14:05 Panel discussion and Q&A
14:05 – 15:00 Session 4: ALL
Chair:  Dr David Brittain
14:05 – 14:20 Topic: MRD testing in B-ALL
Speaker: Dr Daleen Kriel
14:20 – 14:50 Topic: Redefining frontline consolidation in B-cell ALL – the emerging role of immunotherapy in sustaining remission
Speaker: Dr Perry Loebenberg
Sponsored by Aspen
14:50 – 15:00 Panel discussion and Q&A
15:00 – 15:30 Refreshment Break
15:30 – 16:30 Session 5: Oral Presentations 

Chairs: Dr Siphiwe Baloyi & Dr Michael Cass

Dr Marthinus Dicks
Treatment access, survival and healthcare resource utilisation in acquired aplastic anaemia within a South African transplant referral network

Dr Sharlene Parasnath
Acute Leukaemia in KwaZulu-Natal: A 14-Year Provincial Landscape of Disease, Geography, and Survival from a Single Quaternary Centre

Dr Judith T Pazorora
Prevalence and risk factors of aplastic anaemia among patients presenting with pancytopenia at Parirenyatwa haematology units.

Dr David Richardson
Risk Stratification in South African Burkitt Lymphoma: Evaluating and Refining the BL-IPI in a Predominantly HIV-Associated Cohort

Dr Caroline Steyn
Quality of Life Across Hematological Malignancies in Central South Africa: Poor Physical Health in Plasma Cell Neoplasms

16:30 – 16:35 Poster Gallery briefing
16:35 – 17:00 Poster session
17:00 – 18:00 SACHAS AGM
19:30 – 23:45 Conference Dinner
Sunday 04 October 2026
08:00 – 09:00 SYMPOSIUM: Bleeding disorders – Haemophilia and beyond
Sponsored by Novo Nordisk
Chair: Prof Jaco Joubert  
Topic: Factors – more than you think…
Speaker: Dr Jaimendra Singh
Q&A
09:00 – 10:00 Session 6: CML  
Chair: Dr Sharlene Parasnath
09:00 – 09:45 Topic: Beyond Survival: Shared decisions, better lives in CML
Speaker: Prof Vernon Louw
Sponsored by Novartis
09:45 – 10:00 Panel discussion and Q&A
10:00 – 10:30 Refreshment Break
10:30 – 11:30 Session 7: Patient Blood Management  
Chair: Prof Vernon Louw
10:30 – 10:50 Topic: Improved diagnosis of iron deficiency anaemia in the critically ill via fluorescence flow cytometric haemoglobin biomarkers
Speaker: Dr Christian Hönemann
10:50 – 11:10 Topic: Exploring new cellular biomarkers from routine blood count using fluorescence flow cytometric parameters – the potential of the intensive care infection score
Speaker: Dr Christian Hönemann
11:10 – 11:20 Q&A 
11:20 – 12:15 Session 8: Ethics 
Chair: Dr Perry Loebenberg
11:20 – 12:00 Topic: Algorithms at the bedside: The evolution, application and ethics of AI in medicine
Speaker: Prof Jacques Malherbe 
12:00 – 12:15 Q&A 
12:15 – 12:30 Conference Closing 
Prof Vernon Louw
12:30 Light lunch  

Adcock Ingram, a Proudly South African company was founded over 130 years ago in 1891. The Company has an extensive portfolio, including well-known household brands. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes non-price-regulated healthcare, consumer products, a strong presence in over the counter, an extensive portfolio of branded and generic prescription medicines. As the largest supplier to the private sector in South Africa, the Company provides work to more than 2 000 employees. Bidvest Group Limited has a majority ownership with Natco Pharma, an Indian-based pharmaceutical Company, as the other shareholder. Our mission is to provide quality products that improve the health and lives of the people in the markets that we serve.

Hematology is a complex and challenging area of medicine. At Roche, finding innovative solutions for those affected by diseases of the blood is not only a priority, it's in our blood. Our commitment extends beyond developing innovative therapies, to playing a wider role in improving patient's quality of life. We are exploring the best ways to deliver innovations to patients as quickly and effectively as possible, which includes evolving and improving how our clinical trials are designed and how our therapies are administered. We are also looking at new ways to measure treatment success through the use of alternative clinical endpoints.

We continue to invest in bringing innovative treatment options to people with diseases of the blood, as our teams strive to continually deliver transformational change for patients and the physicians who treat them.

https://www.roche.com/solutions/focus-areas/haematoloqy

Roche Products (Pty) Ltd. Reg. No. 1947/027044/07. Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686. P.O. Box
1469, Halfway House, 1685. +27 (0)11 504 4746 or Toll-free on REAL (Roche Ethical Assistance Line): +27 (0)800 21 21 25
M-ZA-00003254 | Expiry Date: August 2028

Aspen is a global specialty and branded pharmaceutical company. With more than 170 years of heritage. Aligned with our ethos “Healthcare. We Care.”, our basket reflects a combination of legacy, innovation, and reliability, positioning Aspen as a preferred and trusted partner in advancing healthcare. We are dedicated to enhancing patient health and quality of life.

BeOne Medicines is a global oncology company dedicated to transforming cancer care through scientific excellence, innovation, and exceptional speed. Our fully integrated model spans discovery, development, manufacturing, and commercialization, enabling us to bring breakthrough therapies to patients faster. With one of the world's largest oncology-focused R&D organizations and a pipeline of more than 45 clinical and commercial-stage assets, we are advancing the future of cancer treatment. Through a commitment to expanding access worldwide, BeOne is working to reach more patients than ever before. Together, we are how the world stops cancer.

To find out more, please visit: www.beonemedicines.co.za

BeOne Medicines South Africa (Pty) Ltd. VilleBois Office Park, Building 2 - 920 De Ville Bois Mareuil Drive, Moreleta Park, X36,Pretoria, Gauteng, 0044, South Africa. Reg. No:1996 / 011587 / 07. Tel: 076 509 0279. Toll-free number: 0800 983 530.

Contact details: For general information: infosa@beonemed.com. Adverse events: patientsafetyza@beonemed.com

BEI-066-0926

Agios is a commercial-stage biopharmaceutical company. The company’s vision is to redefine the future of rare disease treatment. With a foundation in hematology, Agios combines biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people it serves. Visit www.agios.com.
 

About AstraZeneca

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes. We believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Activity ID: ZA-6886; Expiry date: 30 June 2028

https://www.astrazeneca.com/country-sites/african-cluster.html

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built on our heritage in diabetes. Through scientific innovation, expanded access to medicines, and partnerships across healthcare and technology, we help bring meaningful solutions to patients worldwide. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter, Instagram and YouTube.

Loading...